300 related articles for article (PubMed ID: 30893090)
1. Sarcopenic obesity in fatty liver.
Merli M; Lattanzi B; Aprile F
Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.
Polyzos SA; Vachliotis ID; Mantzoros CS
Metabolism; 2023 Oct; 147():155676. PubMed ID: 37544590
[TBL] [Abstract][Full Text] [Related]
3. Verification of the Nutritional and Dietary Factors Associated with Skeletal Muscle Index in Japanese Patients with Nonalcoholic Fatty Liver Disease.
Himoto T; Miyatake K; Maeba T; Masaki T
Can J Gastroenterol Hepatol; 2020; 2020():3576974. PubMed ID: 32695733
[TBL] [Abstract][Full Text] [Related]
4. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity.
Kashiwagi K; Takayama M; Fukuhara K; Shimizu-Hirota R; Chu PS; Nakamoto N; Inoue N; Iwao Y; Kanai T
Clin Nutr ESPEN; 2020 Aug; 38():86-93. PubMed ID: 32690183
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity.
Wijarnpreecha K; Panjawatanan P; Aby E; Ahmed A; Kim D
Maturitas; 2019 Jun; 124():48-54. PubMed ID: 31097179
[TBL] [Abstract][Full Text] [Related]
6. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.
Gan D; Wang L; Jia M; Ru Y; Ma Y; Zheng W; Zhao X; Yang F; Wang T; Mu Y; Zhu S
Clin Nutr; 2020 Apr; 39(4):1124-1130. PubMed ID: 31053512
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia and fatty liver disease.
Kim JA; Choi KM
Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
[TBL] [Abstract][Full Text] [Related]
8. Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis.
Song W; Yoo SH; Jang J; Baik SJ; Lee BK; Lee HW; Park JS
Gut Liver; 2023 Jan; 17(1):130-138. PubMed ID: 36472070
[TBL] [Abstract][Full Text] [Related]
9. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.
Hong HC; Hwang SY; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Hepatology; 2014 May; 59(5):1772-8. PubMed ID: 23996808
[TBL] [Abstract][Full Text] [Related]
10. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.
Zambon Azevedo V; Silaghi CA; Maurel T; Silaghi H; Ratziu V; Pais R
Front Nutr; 2021; 8():774030. PubMed ID: 35111794
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
[TBL] [Abstract][Full Text] [Related]
13. Lean nonalcoholic fatty liver disease and sarcopenia.
Chen M; Cao Y; Ji G; Zhang L
Front Endocrinol (Lausanne); 2023; 14():1217249. PubMed ID: 37424859
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences.
Hong SH; Choi KM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941015
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits.
Emhmed Ali S; Nguyen MH
Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33557355
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
Armandi A; Rosso C; Caviglia GP; Ribaldone DG; Bugianesi E
Front Endocrinol (Lausanne); 2021; 12():716533. PubMed ID: 34858322
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
Mikolasevic I; Pavic T; Kanizaj TF; Bender DV; Domislovic V; Krznaric Z
Can J Gastroenterol Hepatol; 2020; 2020():8859719. PubMed ID: 33204675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
